普拉佐辛增强了上腺素的杆细胞稳定性
Nozomu Abe1, Hiroaki Toyama1, Yutaka Ejima1
1Department of Anesthesiology, Tohoku University Hospital, Seiryo-cho, Aoba-ku, Sendai, Miyagi, Japan.
概括
上腺素通过作用于β-2上腺素受体来抑制杆细胞脱粒化. 用普拉佐辛阻断α-1上腺体受体增强了这种效果,证实了上腺素作为巨细胞稳定剂.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 细胞生物学 细胞生物学
背景情况:
- 上腺素抑制了巨细胞释放的组胺.
- 无论是β-2和α-上腺体受体都涉及杆细胞外细胞形成.
- 可以通过膜电容 (Cm) 的变化通过电生理学监测乳腺细胞外.
研究的目的:
- 为了研究上腺素对巨细胞脱粒的电生理效应.
- 确定阿尔法-上腺素受体在上腺素介导的巨细胞稳定中的作用.
- 为了证实上腺素的杆细胞稳定性.
主要方法:
- 全细胞补丁技术在老鼠腹性巨细胞.
- 在外细胞形成过程中监测膜电容 (Cm) 的变化.
- 在上腺素受体agonists/antagonists的存在下评估杆细胞脱粒化.
主要成果:
- 上腺素剂量依赖抑制了GTP-γ-S诱导的Cm增加和抑制了脱粒化.
- 布托克萨明 (一种β-2抗剂) 几乎消除了上腺素的抑制作用.
- 普拉佐辛 (一种α-1抗剂) 显著降低了脱粒和Cm增加,并强化了上腺素的抑制作用.
结论:
- 上腺素剂量取决于抑制巨细胞外细胞形成,作为强大的巨细胞稳定剂.
- 电生理学证据证实了上腺素的巨细胞稳定能力.
- 阿尔法-1 上腺素受体阻断协同增强上腺素的巨细胞稳定作用,主要由β-2 受体介导.
相关概念视频
Adrenergic Agonists: Therapeutic Uses
766
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
766
Adrenergic Agonists: Mixed-Action Agents
701
Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
701
Drugs Affecting Neurotransmitter Release or Uptake
1.0K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.0K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
2.9K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
2.9K
Adrenergic Agonists: Direct-Acting Agents
1.4K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
These agents can be classified...
1.4K
Adrenergic Receptors: β Subtype
1.6K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
1.6K


